Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib and Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer
NCT00046839Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Jul 2002
- Primary completion
- Sep 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of celecoxib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by NRG Oncology. Primary endpoints: Maximum Tolerated Dose at 90 days and Overall Survival at 12 months. Started Jul 2002; status: completed.
02
Drugs
celecoxib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00046839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046839.